Recombinant Human TIGIT protein, His-Avi-tagged

• Cat.No.: TIGIT-495H
• Product Overview: Recombinant Human TIGIT is expressed from Expi293 with a His tag and Avi Tag at the C-terminal. It contains Met22-Pro141.

Specification

• Description: TIGIT, also called Vstm3, Vsig9, and WUCAM, is a transmembrane protein in the CD28 family of the Ig superfamily proteins. IGIT is expressed at low levels on peripheral memory and regulatory CD4+ T-cells and NK cells and is up-regulated following activation of these cells.
• Source: HEK293
• Species: Human
• Tag: His&Avi
• Form: Supplied as 0.22μm filtered solution in PBS (pH 7.4).
• Molecular Mass: The protein has a predicted MW of 16.1kDa. Due to glycosylation, the protein migrates to 20-25kDa based on Bis-Tris PAGE result.
• Protein length: Met22-Pro141
• Endotoxin: Less than 0.1EU per μg by the LAL method.
• Purity: >95% as determined by SDS-PAGE; >95% as determined by HPLC
• Storage: The product should be stored at -70°C. Please do not repeated freeze-thaw cycles.

Gene Information

• Gene Name: TIGIT
• Official Symbol: TIGIT
• Synonyms: TIGIT, VSIG9, VSTM3, WUCAM, T cell immunoreceptor with Ig and ITIM domains
• Gene ID: 201633
• mRNA Refseq: NM_173799.4
• Protein Refseq: NP_776160.2
• MIM: 612859
• UniProt ID: Q495A1

Reviews

11/25/2022

With its well-characterized nature and availability in various formats, the TIGIT protein is an advantageous tool that aids researchers in achieving their scientific goals.

08/05/2017

Whether it's troubleshooting issues, optimizing experimental protocols, or providing detailed information about the protein, the manufacturer's support team is dedicated to helping researchers overcome any challenges they may encounter.

05/21/2017

The manufacturer also ensures that the TIGIT protein is well-characterized, with extensive documentation on its functional properties.

Q&As

In which types of cancers is TIGIT inhibition being investigated?

TIGIT inhibitors are being studied in a range of cancers, including lung cancer, breast cancer, and melanoma, among others.

How is TIGIT relevant in autoimmune diseases?

TIGIT is being explored as a potential target for treating autoimmune diseases by modulating immune responses to prevent excessive inflammation.

What clinical applications does TIGIT have in cancer therapy?

TIGIT is being explored as a potential target for cancer immunotherapy, with drugs designed to block TIGIT and enhance the immune system's ability to attack cancer cells.

How does TIGIT differ from other immune checkpoint proteins like PD-1 and CTLA-4?

TIGIT operates as an immune checkpoint, similar to PD-1 and CTLA-4, but it has distinct mechanisms of action and may regulate different aspects of the immune response.

Are there any potential side effects associated with TIGIT-targeted therapies?

As with any immunotherapy, potential side effects may include immune-related adverse events such as inflammation in various organs, but the specific profile is still under investigation.